Find Reports

Select Report Type

Reimbursement Review

Displaying 351 - 375 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
budesonide	Jorveza	budesonide	SR0634 Jorveza - CDEC Final Recommendation October 30, 2020_for posting.pdf sr0634-jorveza-clinical-review-report.pdf sr0634-jorveza-pharmacoeconomic-review-report.pdf SR0634_Jorveza_PI_Submission.pdf	Eosinophilic esophagitis, adults	Reimburse with clinical criteria and/or conditions	Complete	Nov 8, 2019	Oct 28, 2020	SR0634-000
Halobetasol propionate and taz...	Duobrii	Halobetasol propionate and tazarotene	SR0638 Duobrii - CDEC Final Recommendation October 30, 2020_For Posting.pdf sr0638-duobrii-clinical-review-report.pdf sr0638-duobrii-parmacoeconomic-review-report.pdf SR0638 Duobrii - Patient Input_For posting.pdf	Psoriasis, moderate to severe plaque	Reimburse with clinical criteria and/or conditions	Complete	Jan 24, 2020	Oct 28, 2020	SR0638-000
etonogestrel	Nexplanon	etonogestrel	SR0648 Nexplanon - CDEC Final Recommendation October 22, 2020_for posting.pdf sr0648-nexplanon-clinical-review-report.pdf sr0648-nexplanon-pharmacoeconomic-review-report.pdf	Prevention of pregnancy	Reimburse with clinical criteria and/or conditions	Complete	Jun 3, 2020	Oct 20, 2020	SR0648-000
eculizumab	Soliris	eculizumab	SR0605 Soliris MG - CDEC Final Recommendation October 21, 2020_for posting.pdf sr0605-soliris-mg-clinical-review-report.pdf sr0605-soliris-mg-pharmacoeconomic-review-report.pdf SR0605_Soliris MG_PI Submission.pdf	Myasthenia Gravis (gMG), adults	Reimburse with clinical criteria and/or conditions	Complete	Apr 1, 2020	Oct 19, 2020	SR0605-000
Enzalutamide (Xtandi) for Meta...	Xtandi	Enzalutamide	10209EnzalutamidemCSPC_fnRec_EarlyConv_REDACT_ApprovedbyChair_Post23Sep2020_final.pdf 10209EnzalutamidemCSPC_fnEGR_REDACT-ABBREV_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_fnCGR_REDACT_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_inRec_approvedbyChair_REDACT_Post_03Sep2020_final.pdf 10209EnzalutamidemCSPC_PAGFeedbackSummary_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_SponsorFeedback_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_ClinicianFeedback_CCO_Post_23Sep2020_final.pdf 10209EnzalutamidemCSPC_COI_CCS_Post_23Sep2020_final.pdf Enzalutamide (Xtandi) mCSPC – PAG Feedback on Initial Recommendation - Feedback Enzalutamide (Xtandi) mCSPC – Clinician COI Declarations	mHSPC	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2020	Sep 23, 2020	PC0209-000
Niraparib (Zejula) for Ovarian...	Zejula	Niraparib	10203NiraparibOC_fnRec_pERC Chair Approved_Post_03Sep2020_final.pdf 10203NiraparibOC_fnEGR_REDACTABBREV_Post03Sep2020_final.pdf 10203NiraparibOC_fnCGR_REDACT_Post_03Sep2020_final.pdf 10203NiraparibOC_InitialRec_Approved_03Jul2020_final.pdf 10203NiraparibOC_PAGFeedbackSummary_Post03Sep2020_final.pdf 10203NiraparibOC_SponsorFeedback_2020-17-07_Post03Sep2020_final_Redacted.pdf 10203NiraparibOC_PatientFeedback_OCC_2020-14-07_Post03Sep2020_final.pdf 10203NiraparibOC_ClinicianFeedback_CCO_2020-17-07_Post03Sep2020_final_Redacted.pdf 10203NiraparibOC_PatientInput_OCC_2020-02-24_revised_Post03Sep2020_final.pdf 10203NiraparibOC_CombinedClinician COIs_Post03Sep2020_final_Redacted.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 7, 2020	Sep 3, 2020	PC0203-000
caplacizumab	Cablivi	caplacizumab	SR0633 Cablivi - CDEC Final Recommendation September 1, 2020 for posting.pdf sr0633-cablivi-clinical-review-report.pdf sr0633-cablivi-pharmacoeconomic-review-report.pdf Cablivi - Patient Group Input for posting.pdf	Acquired thrombotic thrombocytopenic purpura (aTTP)	Do not reimburse	Complete	Sep 13, 2019	Aug 26, 2020	SR0633-000
eculizumab	Soliris	eculizumab	SR0640 Soliris - CDEC Final Recommendation August 24, 2020 for posting.pdf sr0640-soliris-nmosd-clinical-review-report.pdf sr0640-soliris-nmosd-pharmacoeconomic-review-report.pdf SR0640_Soliris NMOSD_PI Submission.pdf	Neuromyelitis optica spectrum disorder	Reimburse with clinical criteria and/or conditions	Complete	Feb 25, 2020	Aug 19, 2020	SR0640-000
erenumab	Aimovig	erenumab	SR0578 Aimovig - CDEC Final Recommendation July 24, 2020 (redacted)_For Posting.pdf sr0578-aimovig-clinical-review-report.pdf sr0578-aimovig-pharmacoeconomic-review-report.pdf SR0578-Aimovig-patient-input.pdf	Migraine	Reimburse with clinical criteria and/or conditions	Complete	May 2, 2019	Jul 22, 2020	SR0578-000
cabotegravir/rilpivirine	Vocabria and Cabenuva	cabotegravir sodium cabotegravir-rilpivirine	SR0628 Vocabria + Cabenuva - Final CDEC Recommendation September 9, 2020_for posting.pdf SR0628 cabotegravir + rilpivirne - Group Patient Input_October 21, 2019.pdf sr0628-vocabria+cabenuva-clinical-review-report-QC_redacted-gg.pdf sr0628-vocabria+cabenuva-pharmacoeconomic-review-report.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Aug 19, 2019	Jul 22, 2020	SR0628-000
siponimod	Mayzent	siponimod	SR0631_Mayzent_PI Submission.pdf SR0631 Mayzent - CDEC Final Recommendation July 23, 2020 (redacted)_For posting.pdf sr0631-mayzent-clinical-review-report.pdf sr0631-mayzent-pharmacoeconomic-review-report.pdf	Secondary progressive multiple sclerosis	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	Jul 21, 2020	SR0631-000
ustekinumab	Stelara/Stelara I.V	ustekinumab	SR0627_Stelara UC_PI Submission.pdf SR0627 Stelara - CDEC Final Recommendation July 20, 2020_for posting.pdf sr0627-stelara-clinical-review-report.pdf sr0627-stelara-pharmacoeconomic-review-report.pdf	Ulcerative colitis	Reimburse with clinical criteria and/or conditions	Complete	Aug 12, 2019	Jul 16, 2020	SR0627-000
icosapent ethyl	Vascepa	icosapent ethyl	SR0619 Vascepa - CDEC Final Recommendation July 20, 2020_for posting.pdf sr0619-vascepa-clinical-review-report.pdf sr0619-vascepa-pharmacoeconomic-review-report.pdf	Ischemic events in statin-treated patients	Reimburse with clinical criteria and/or conditions	Complete	Jun 17, 2019	Jul 16, 2020	SR0619-000
Tecentriq & Avastin Non-Sq...	Tecentriq & Avastin	Atezolizumab & Bevacizumab	10155AtezolizumabBevacizumabNSQ-NSCLC_FinalRec_Post03July2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_fnEGR_REDACT-ABBREV_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_fnCGR_REDACT_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_inRec_REDACT_pERC Chair Approved_Post30Apr2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_PAGFeedbackSummary_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_SponsorFeedback_Post03Jul2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_PatientFeedback_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_Combined ClinicianFeedback_Post03Jul2020_final_Redacted.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_COI_LCC_Post03Jul2020_final.pdf 10155AtezolizumabBevacizumabNSQ-NSCLC_Combined COIs_Post03Jul2020_final_Redacted.pdf	NSQ-NSCLC	Do not reimburse	Complete	Nov 18, 2019	Jul 3, 2020	PC0155-000
glycopyrrolate	Cuvposa	glycopyrrolate	SR0613 Cuvposa - CDEC Final Recommendation June 26, 2020_for posting.pdf sr0613-cuvposa-pharmacoeconomic-review-report.pdf sr0613-cuvposa-clinical-review-report.pdf	chronic severe drooling, neurologic (pediatric)	Do not reimburse	Complete	May 31, 2019	Jun 24, 2020	SR0613-000
Kisqali for Advanced or Metast...	Kisqali	Ribociclib	RibociclibKisqali_MBC10194ProvFunding.pdf 10194RibociclibMBC_FnRec_Chair Approved_Post04Jun2020_final.pdf 10194RibociclibMBC_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf 10194RibociclibMBC_fnCGR_NOREDACT_Post04Jun2020_final.pdf 10194RibociclibMBC_inRec_pERC Chair Approved_Post02Apr2020_final.pdf 10194RibociclibMBC_PAGFeedbackSummary_Post04Jun2020_final.pdf 10194RibociclibMBC_SponsorFeedback_Post04Jun2020_final.pdf 10194RibociclibMBC_Combined_PatientFeedback_Post04Jun2020_final_Redacted.pdf 10194RibociclibMBC_ClinicianFeedback_CCO_Post04Jun2020_final_Redacted.pdf 10194RibociclibMBC_Combined COI_Redacted.pdf 10194RibociclibMBC_Clinician Combined COI_Redacted.pdf	HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Jun 4, 2020	PC0194-000
Brentuximab Vedotin (Adcetris)...	Adcetris	Brentuximab Vedotin	BrentuximabVedotinAdcetris_PTCL10199ProvFunding.pdf 10199BrentuximabVedotinPTCL_FnRec_approved_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_fnEGR_NOREDACT-ABBREV_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_fnCGR_NOREDACT_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_inRec_approvedbyChair_NOREDACT_Post02Apr2020_final.pdf 10199BrentuximabVedotinPTCL_PAGFeedbackSummary_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_SponsorFeedback_Post04Jun2020_final_Redacted.pdf 10199BrentuximabVedotinPTCL_PatientFeedback_LC_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_ClinicianFeedback_CCO_Post02Jun2020_final_Redacted.pdf 10199BrentuximabVedotinPTCL_Patient_COI_LC_Post04Jun2020_final.pdf 10199BrentuximabVedotinPTCL_Combined_Clinician_COIs_Post04Jun2020_final_Redacted.pdf	peripheral T-cell lymphoma (PTCL)	Reimburse	Complete	Oct 8, 2019	Jun 4, 2020	PC0199-000
burosumab	Crysvita	burosumab	SR0602 Crysvita - CDEC Final Recommendation May 29, 2020_For posting.pdf sr0602-crysvita-clinical-review-report.pdf sr0602-crysvita-pharmacoeconomic-review-report.pdf Crysvita - Patient Group Input - For posting.pdf	Treatment of X-Linked Hypophosphatemia	Reimburse with clinical criteria and/or conditions	Complete	Jul 23, 2019	May 27, 2020	SR0602-000
naltrexone hydrochloride and b...	Contrave	naltrexone hydrochloride and bupropion hydrochloride	SR0610 Contrave - CDEC Final Recommendation June 5, 2020 Final_for posting.pdf sr0610-contrave-clinical-review-report.pdf sr0610-contrave-pharmacoeconomic-review-report.pdf SR0610 Contrave - Patient Group Input June 17, 2019.pdf	Chronic weight management in adults	Do not reimburse	Complete	May 1, 2019	May 27, 2020	SR0610-000
brolucizumab	Beovu	brolucizumab	SR0632 Beovu - CDEC Final Recommendation – May 25, 2020_for posting.pdf sr0632-beovu-clinical-review-report.pdf sr0632-beovu-pharmacoeconomic-review-report.pdf SR0632_Brolucizumab_PI Submission.pdf	Macular degeneration, age-related	Reimburse with clinical criteria and/or conditions	Complete	Sep 26, 2019	May 21, 2020	SR0632-000
Gilteritinib (Xospata) for Acu...	Xospata	Gilteritinib	GilteritinibXospata__AML10102_ProvFunding.pdf 10202GilteritinibAML_FnRec_REDACT_EarlyConv_20May2020_final.pdf 10202GilteritinibAML_fnCGR_REDACT_EarlyConv_20May2020_final.pdf 10202GilteritinibAML_fnEGR_REDACT-ABBREV_EarlyConv20May2020_final.pdf 10202GilteritinibAML_inRec_REDACT_ApprovedbyChair_Post30Apr2020_final.pdf 10202GilteritinibAML_PAGFeedbackSummary_Post20May2020_final.pdf 10202GilteritinibAML_SponsorFeedback_Post20May2020_final.pdf 10202GilteritinibAML_PatientFeedback_LLSC_Post20May2020_final_Redacted.pdf 10202GilteritinibAML_ClinicianFeedback_CCODAC_Post20May2020_final.pdf 10202GilteritinibAML_COI-LLSC_Post20May2020_final.pdf 10202GilteritinibAML_Combined_ClincianInput_Post20May2020_final_Redacted.pdf		Reimburse with clinical criteria and/or conditions	Complete	Oct 28, 2019	May 20, 2020	PC0202 -000
vedolizumab	Entyvio	vedolizumab	SR0635 Entyvio - CDEC Final Recommendation – May 21, 2020_for posting.pdf sr0635-entyvio-clinical-review-report.pdf sr0635-entyvio-pharmacoeconomic-review-report.pdf SR0635_Entyvio_PI Submission.pdf	Ulcerative Colitis	Reimburse with clinical criteria and/or conditions	Complete	Nov 21, 2019	May 19, 2020	SR0635-000
Apalutamide (Erleada) for Meta...	Erleada	Apalutamide	ApalutamideErleada_mCSPC10200ProvFunding.pdf 10200ApalutamidemCSPC_fnRec_ChairApproved_EarlyConv_22Apr2020_final.pdf 10200ApalutamidemCSPC_fnEGR_REDACT-ABBREV_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_fnCGR_REDACT__EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_inRec_ApprovedbyChair_Post02Apr2020_final-updated.pdf 10200ApalutamidemCSPC_PAGFeedbackSummary_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_SponsorFeedback_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC COICCSN_EC_22Apr2020_final.pdf 10200ApalutamidemCSPC_COI_Combined_Clinician Redacted.pdf	metastatic castration-sensitive prostate cancer (mCSPC)	Reimburse with clinical criteria and/or conditions	Complete	Oct 15, 2019	Apr 22, 2020	PC0200-000
Cabozantinib (Cabometyx) for H...	Cabometyx	Cabozantinib	10186CabozantinibHCC_FnRec_EC_22Apr2020_final.pdf 10186CabozantinibHCC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf 10186CabozantinibHCC_inCGR_NOREDACT_EC_22Apr2020_final.pdf 10186CabozantinibHCC_inRec_2020-04-01_ApprovedbyChair_Post02Apr2020_final.pdf 10186CabozantinibHCC_PAGFeedbackSummary_EC_22Apr2020_final.pdf 10186CabozantinibHCC_SponsorFeedback_EC_22Apr2020_final.pdf 10186CabozantinibHCC_Combined ClinicianFeedback_EC_22Apr2020_final.pdf 10186CabozantinibHCC_COI CLF_EC_22Apr2020_final.pdf 10186CabozantinibHCC_Combined COI_EC_22Apr2020_final_Redacted.pdf	HCC	Reimburse with clinical criteria and/or conditions	Complete	Oct 16, 2019	Apr 22, 2020	PC0186-000
Kisqali (with Fulvestrant) for...	Kisqali	Ribociclib with Fulvestrant	RibociclibKisqali+Fulvestrant_MBC10195ProvFunding.pdf 10195RibociclibFulvestrantMBC_fnRec_pERC Chair Approved_22April2020_final.pdf 10195RibociclibFulvestrantMBC_fnEGR_NOREDACT-ABBREV_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_fnCGR_NOREDACT_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_inRec_pERC Chair Approved_Post02Apr2020_final.pdf 10195RibociclibFulvestrantMBC_PAGFeedbackSummary__EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_SponsorFeedback_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_Combined_PatientFeedback.pdf 10195RibociclibFulvestrantMBC_ClinicianFeedback_CCO_EC_22Apr2020_final.pdf 10195RibociclibFulvestrantMBC_Combined COIs_EC_22Apr2020_final_Redacted.pdf 10195RibociclibFulvestrantMBC_Combined Clinician COI_EC_22Apr2020_final_Redacted.pdf	+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer	Reimburse with clinical criteria and/or conditions	Complete	Aug 26, 2019	Apr 22, 2020	PC0195-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 351 - 375 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Hip Protectors for Community-Dwelling Older Adults	Hip Protectors for Community-Dwelling Older Adults	Sep 2, 2021	Rapid Review	Completed	RC1378-000
Anesthesia Care Provided by Nurses	Anesthesia Care Provided by Nurses	Sep 2, 2021	Rapid Review		RC1376-000
Shortened Drug Regimens for the Treatment of Active Tuberculosis	Shortened Drug Regimens for the Treatment of Active Tuberculosis	Aug 30, 2021	Summary with Critical Appraisal	Completed	RC1342-000
Prevention of Tuberculosis Reactivation	Prevention of Tuberculosis Reactivation	Aug 27, 2021	Rapid Review	Completed	RC1344-000
Medications Containing Low-dose Codeine for the Treatment of Pain and Coughs	Medications Containing Low-dose Codeine for the Treatment of Pain and Coughs	Aug 20, 2021	Rapid Review	Completed	RC1374-000
The Use of Cone Beam CT in Dental, Oral, and Maxillofacial Surgery, and Otolaryngology Settings	The Use of Cone Beam CT in Dental, Oral, and Maxillofacial Surgery, and Otolary…	Aug 11, 2021	Environmental Scan	Completed	ES0348-000
Chlorhexidine Gluconate for Skin Preparation During Catheter Insertion and Surgical Procedures	Chlorhexidine Gluconate for Skin Preparation During Catheter Insertion and Surg…	Aug 10, 2021	Rapid Review		RC1375-000
Community Pharmacist–Led Medication Reviews	Community PharmacistñLed Medication Reviews	Aug 9, 2021	Policy Insight	Completed	CY0005-000
Sustainability of Chronic Kidney Disease Care	Sustainability of Chronic Kidney Disease Care	Aug 6, 2021	Policy Insight	Completed	CY0011-000
Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Health Facilities or Emergency Department Settings	Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Heal…	Aug 5, 2021	Rapid Review	Completed	RC1373-000
Autologous Hematopoietic Cell Transplant for Patients With Multiple Sclerosis	Summary With Critical Appraisal - Rapid Response Report	Aug 5, 2021	Rapid Review		RC1356-000
Harm Reduction Interventions to Prevent Overdose	Harm Reduction Interventions to Prevent Overdose	Aug 5, 2021	Policy Insight	Completed	CY0008-000
Vitamin D Supplementation for the Prevention of Falls and Fractures in Residents of Long-Term Care Facilities: A 2021 Update	RC1371 VitD in LTC Fall Prevention Update Final.pdf	Jul 29, 2021	Rapid Review	Completed	RC1371-000
Point-of-Care Testing and N-Acetylcysteine for Acute Acetaminophen Overdose	Point-of-Care Testing and N-Acetylcysteine for Acute Acetaminophen Overdose	Jul 28, 2021	Rapid Review	Completed	RC1372-000
Vitamin D Supplementation for the Prevention and/or Treatment of Cardiovascular Disease, Cancer, and Other Conditions in Residents of Long-Term Care Facilities	Vitamin D Supplementation for the Prevention and/or Treatment of Cardiovascular…	Jul 28, 2021	Rapid Review	Completed	RC1370-000
Convalescent Plasma Therapy for the Treatment of COVID-19: A Review of Clinical Effectiveness	RC1288-007 Convalescent Plasma COVID_Final.pdf	Jul 26, 2021	Rapid Review	Completed	RC1288-007
Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Aortic Stenosis	Transcatheter Aortic Valve Implantation for Patients with Severe Symptomatic Ao…	Jul 21, 2021	Summary with Critical Appraisal		RC1367-000
Palonosetron for Patients Undergoing High or Moderate Emetogenic Chemotherapy	Palonosetron for Patients Undergoing High or Moderate Emetogenic Chemotherapy	Jul 21, 2021	Summary with Critical Appraisal	Completed	RC1366-000
Implementation of Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer in Canada	Implementation of Stereotactic Ablative Radiotherapy for the Treatment of Oligo…	Jul 14, 2021	Environmental Scan	Completed	ES0352-000
Long-Term Care Personal Support Workers’ Resilience and Wellness	Long-Term Care Personal Support Workers’ Resilience and Wellness	Jul 9, 2021		Completed
Strategies Used by Long-Term Care Facilities to Maintain Communication With Essential Care Partners During a Pandemic or Infectious Disease Outbreak	Strategies Used by Long-Term Care Facilities to Maintain Communication With Ess…	Jul 8, 2021		Completed
Genetic Carrier Screening for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies, and Spinal Muscular Atrophy	RC1361_Genetic Carrier Screening Final.pdf	Jun 25, 2021	Rapid Review		RC1361-000
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders	RC1363 Psychedelics Final.pdf	Jun 25, 2021	Rapid Review	Completed	RC1363-000
Interventions to Address and Prevent Violence Toward Health Care Workers in the Emergency Department	Interventions to Address and Prevent Violence Toward Health Care Workers in the…	Jun 24, 2021	Rapid Review	Active	RC1362
Hybrid Closed-Loop Insulin Delivery Systems for People with Type 1 Diabetes	OP0548 HCL Rec v. 7.0-pw.pdf op0548-hcl-consolidated-report-appendices-7.0.pdf de0104-hcl-insulin-scoping-brief-final.pdf op0548-hybrid-closed-loop-insulin-for-t1dm-update.pdf op0548-hybrid-close-loop-he-protocol-amendment-sep14.pdf	Jun 23, 2021	Optimal Use	Complete	OP0548-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 351 - 375 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Drug Shortages in Canada	Final Report	Jul 31, 2024	Health Technology Review	Environmental Scan	Completed	ES0381-000
drospirenone	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Jul 26, 2024	Reimbursement Review		Complete	SR0806-000
Pharmaceutical Reviews Update — Issue 49		Jul 25, 2024	Reimbursement Review	Pharmaceutical Review Update
solriamfetol		Jul 24, 2024	Reimbursement Review		Not filed	NS0039-000
solriamfetol		Jul 24, 2024	Reimbursement Review		Not filed	NS0038-000
zanubrutinib		Jul 24, 2024	Reimbursement Review		Not filed	NS0037-000
trastuzumab deruxtecan		Jul 24, 2024	Reimbursement Review		Not filed	NS0035-000
capmatinib		Jul 24, 2024	Reimbursement Review		Not filed	NS0036-000
pembrolizumab		Jul 24, 2024	Reimbursement Review		Not filed	NS0034-000
daratumumab		Jul 24, 2024	Reimbursement Review		Not filed	NS0031-000
liraglutide		Jul 24, 2024	Reimbursement Review		Not filed	NS0032-000
dexamethasone intravitreal implant		Jul 24, 2024	Reimbursement Review		Not filed	NS0033-000
dabrafenib and trametinib		Jul 24, 2024	Reimbursement Review		Not filed	NS0029-000
treosulfan		Jul 24, 2024	Reimbursement Review		Not filed	NS0030-000
omalizumab		Jul 24, 2024	Reimbursement Review		Not filed	NS0026-000
mepolizumab		Jul 24, 2024	Reimbursement Review		Not filed	NS0027-000
dabrafenib and trametinib		Jul 24, 2024	Reimbursement Review		Not filed	NS0028-000
sofosbuvir / velpatasvir		Jul 24, 2024	Reimbursement Review		Not filed	NS0024-000
fluticasone furoate/umeclidinium bromide/vilanterol trifenatate		Jul 24, 2024	Reimbursement Review		Not filed	NS0025-000
Rivaroxaban (granules for oral suspension)		Jul 24, 2024	Reimbursement Review		Not filed	NS0022-000
glecaprevir / pibrentasvir		Jul 24, 2024	Reimbursement Review		Not filed	NS0023-000
clofarabine		Jul 24, 2024	Reimbursement Review		Not filed	NS0020-000
dapagliflozin		Jul 24, 2024	Reimbursement Review		Not filed	NS0021-000
galcanezumab		Jul 24, 2024	Reimbursement Review		Not filed	NS0019-000
talazoparib		Jul 24, 2024	Reimbursement Review		Not filed	NS0017-000